Publications by authors named "Kerry Burnstein"

Claim this Profile
R
RAC1 signaling in prostate cancer: VAV GEFs take center stage.
Mariana Cooke, Nahuel Peinetti, Marcelo G Kazanietz, Kerry L Burnstein

Front Cell Dev Biol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges and opportunities in training cancer researchers.
Brian Keith, Danny R Welch, Nishtha Agarwal, Caroline Blair, Ifeanyi Beverly Chukwudozie, Kerry L Burnstein

Nat Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan-Cancer Drug Sensitivity Prediction from Gene Expression using Deep Learning.
Beronica A Ocasio, Jiaming Hu, Vasileios Stathias, Maria J Martinez, Kerry L Burnstein

bioRxiv· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023.
Thomas P Burris, Ian Mitchelle S de Vera, Isabelle Cote, Colin A Flaveny, Udayanga S Wanninayake, Kerry L Burnstein

Pharmacol Rev· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Automation, live-cell imaging, and endpoint cell viability for prostate cancer drug screens.
Rolando D Z Lyles, Maria J Martinez, Benjamin Sherman, Stephan Schürer, Kerry L Burnstein

PLoS One· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of the serine/threonine kinase BUB1 reverses taxane resistance in prostate cancer.
Maria J Martinez, Rolando D Z Lyles, Nahuel Peinetti, Alex M Grunfeld, Kerry L Burnstein

iScience· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accurate and Early Metastases Diagnosis in Live Animals With Multimodal X-ray and Optical Imaging.
Jiahao Chen, Ning Zhao, Valeria Copello, Yi Ru, Kerry L Burnstein

Int J Radiat Oncol Biol Phys· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is androgen receptor activity in metastatic prostate cancer a good biomarker for bipolar androgen therapy?
Nahuel Peinetti, Marijo Bilusic, Kerry L Burnstein

J Clin Invest· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploiting Dependence of Castration-Resistant Prostate Cancer on the Arginine Vasopressin Signaling Axis by Repurposing Vaptans.
Laine M Heidman, Nahuel Peinetti, Valeria A Copello, Kerry L Burnstein

Mol Cancer Res· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The kinesin KIF20A promotes progression to castration-resistant prostate cancer through autocrine activation of the androgen receptor.
Valeria A Copello, Kerry L Burnstein

Oncogene· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer.
Ning Zhao, Stephanie O Peacock, Chen Hao Lo, Laine M Heidman, Meghan A Rice, Kerry L Burnstein

Sci Transl Med· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced Arginyltransferase 1 is a driver and a potential prognostic indicator of prostate cancer metastasis.
Michael D Birnbaum, Ning Zhao, Balaji T Moorthy, Devang M Patel, Oleksandr N Kryvenko, Kerry L Burnstein

Oncogene· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alterations of tumor microenvironment by nitric oxide impedes castration-resistant prostate cancer growth.
Himanshu Arora, Kush Panara, Manish Kuchakulla, Shathiyah Kulandavelu, Kerry L Burnstein

Proc Natl Acad Sci U S A· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of an oncogenic network with prognostic and therapeutic value in prostate cancer.
Fiorella Magani, Eric R Bray, Maria J Martinez, Ning Zhao, Valeria A Copello, Kerry L Burnstein

Mol Syst Biol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.
Jun Luo, Gerhardt Attard, Steven P Balk, Charlotte Bevan, Kerry Burnstein

Eur Urol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting AR Variant-Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities.
Fiorella Magani, Stephanie O Peacock, Meghan A Rice, Maria J Martinez, Ann M Greene, Kerry L Burnstein

Mol Cancer Res· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thioredoxin-1 protects against androgen receptor-induced redox vulnerability in castration-resistant prostate cancer.
Govindi J Samaranayake, Clara I Troccoli, Mai Huynh, Rolando D Z Lyles, Karen Kage, Kerry L Burnstein

Nat Commun· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity.
Thirupandiyur S Udayakumar, Radka Stoyanova, Mohammed M Shareef, Zhaomei Mu, Sakhi Philip, Kerry L Burnstein

Mol Cancer Ther· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Essential Components of Cancer Education.
Danny R Welch, Toni M Antalis, Kerry Burnstein, Linda Vona-Davis, Roy A Jensen

Cancer Res· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel calcium-dependent mechanism of acquired resistance to IGF-1 receptor inhibition in prostate cancer cells.
Cale D Fahrenholtz, Ann M Greene, Pedro J Beltran, Kerry L Burnstein

Oncotarget· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Coactivator MYST1 regulates nuclear factor-κB and androgen receptor functions during proliferation of prostate cancer cells.
Anbalagan Jaganathan, Pratima Chaurasia, Guang-Qian Xiao, Marc Philizaire, Xiang Lv, Kerry L Burnstein

Mol Endocrinol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VAV3 mediates resistance to breast cancer endocrine therapy.
Helena Aguilar, Ander Urruticoechea, Pasi Halonen, Kazuma Kiyotani, Taisei Mushiroda, Kerry L Burnstein

Breast Cancer Res· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer.
Cale D Fahrenholtz, Ferenc G Rick, Maria I Garcia, Marta Zarandi, Ren-Zhi Cai, Kerry L Burnstein

Proc Natl Acad Sci U S A· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The microRNA -23b/-27b cluster suppresses the metastatic phenotype of castration-resistant prostate cancer cells.
Reema A Ishteiwy, Toby M Ward, Derek M Dykxhoorn, Kerry L Burnstein

PLoS One· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts.
Cale D Fahrenholtz, Pedro J Beltran, Kerry L Burnstein

Mol Cancer Ther· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis